等待开盘 12-19 09:30:00 美东时间
-0.125
-8.12%
Neuronetics, Inc. announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The company, a leader in neurohealth therapies, provides non-drug treatments for mental health conditions, including NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD). The therapy is FDA-cleared and supported by extensive c...
11-20 13:30
Neuronetics announces TRICARE policy expansion to include TMS for adolescents aged 15 and older across 26 states, providing a non-drug depression treatment option for children of military families, supported by clinical evidence and FDA clearance.
11-12 15:33
Neuronetics (NASDAQ:STIM) sees Q4 sales of $40.000 million-$43.000 million vs $43.057 million analyst estimate.
11-04 20:08
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 26.21 percent. This is a 70.45 percent increase over losses of $(0.44) per share from the
11-04 20:06
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Neuronetics, Inc. has granted inducement awards in the form of restricted stock units (RSUs) to twelve new employees. The awards, totaling 1,500 RSUs each for most employees, with some receiving higher amounts, were approved by the company’s Compensation Committee as a material inducement to their employment. The RSUs vest over three years, contingent on continued employment through each vesting date, and are subject to the terms of the company’s...
10-31 20:30
Neuronetics and Elite DNA Behavioral Health have entered a three-year exclusive agreement making Neuronetics the sole provider of transcranial magnetic stimulation (TMS) devices across Elite DNA’s 30+ locations. The collaboration includes expanded fee-based services like patient support, consultations, and scheduling, leveraging Neuronetics’ Greenbrook platform to enhance efficiency and patient care. The partnership aims to expand access to life-...
10-30 12:32
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of
09-17 20:41
New York State Medicaid will begin covering Transcranial Magnetic Stimulation (TMS) services for adults with major depressive disorder (MDD) starting October 1, 2025, for fee-for-service members and November 1, 2025, for Managed Care Plan enrollees. This decision benefits nearly 1 million fee-for-service Medicaid members and over 4.4 million Managed Care参保者, making TMS more accessible to those who need it most. TMS is an evidence-based, non-drug ...
09-17 12:32
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-13 19:10